Comprehensive Analysis of Splicing Factor SRs-related Gene Characteristics: Predicting Osteosarcoma Prognosis and Immune Regulation Status

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Sep 17

PMID 39286028

Authors

Changhai Long

Biao Ma

Kai Li

Sijing Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the impact of SRs-related genes on the overall survival and prognosis of osteosarcoma patients through bulk and single-cell RNA-seq transcriptome analysis.

Methods: In this study, we constructed a prognosis model based on serine/arginine-rich splicing factors (SRs) and predicted the survival of osteosarcoma patients. By analyzing single-cell RNA sequencing data and applying AUCell enrichment analysis, we revealed oncogenic pathways of SRs in osteosarcoma immune cells. Additionally, we described the regulatory role of SRSF7 in pan-cancer.

Results: Lasso regression analysis identified 6 key SRs-related genes, and a prognosis prediction model was established. The upregulation of these pathways revealed that SRs promote tumor cell proliferation and survival by regulating related signaling pathways and help tumor cells evade host immune surveillance. Additionally, by grouping single-cell data using AUCell, we found significant differences in T cell expression between high and low-risk groups. The analysis results indicated that the regulatory activity of SRs is closely related to T cell function, particularly in regulating immune responses and promoting immune evasion. Furthermore, SRSF7 regulates cell proliferation and apoptosis.

Conclusion: SRs-related genes play a critical regulatory role in osteosarcoma. T cells are key in regulating immune responses and promoting immune evasion through SRs genes. SRSF7 is a significant gene influencing the occurrence and development of osteosarcoma.

References

Cheng J, Smyth G, Chen Y . Unraveling the timeline of gene expression: A pseudotemporal trajectory analysis of single-cell RNA sequencing data. F1000Res. 2023; 12:684. PMC: 10663991. DOI: 10.12688/f1000research.134078.2. View

Zheng X, Peng Q, Wang L, Zhang X, Huang L, Wang J . Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer. Int J Biol Sci. 2020; 16(13):2442-2453. PMC: 7378643. DOI: 10.7150/ijbs.46751. View

Wang H, Liu H, Wang L, Xu S, Pi H, Cheng Z . Subtype Classification and Prognosis Signature Construction of Osteosarcoma Based on Cellular Senescence-Related Genes. J Oncol. 2022; 2022:4421952. PMC: 9467774. DOI: 10.1155/2022/4421952. View

Wan B, Wang R, Nie J, Sun Y, Zhang B, Liu W . Analysis of Immune Gene Expression Subtypes Reveals Osteosarcoma Immune Heterogeneity. J Oncol. 2021; 2021:6649412. PMC: 7939746. DOI: 10.1155/2021/6649412. View

Dang C, ODonnell K, Zeller K, Nguyen T, Osthus R, Li F . The c-Myc target gene network. Semin Cancer Biol. 2006; 16(4):253-64. DOI: 10.1016/j.semcancer.2006.07.014. View

Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B . Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003; 21(10):2011-8. DOI: 10.1200/JCO.2003.08.132. View

Lin W, Chen W, Zhong J, Ueki H, Xu A, Watanabe M . Identification of MICALL2 as a Novel Prognostic Biomarker Correlating with Inflammation and T Cell Exhaustion of Kidney Renal Clear Cell Carcinoma. J Cancer. 2022; 13(4):1214-1228. PMC: 8899381. DOI: 10.7150/jca.66922. View

Liu W, Li D, Lu T, Zhang H, Chen Z, Ruan Q . Comprehensive analysis of RNA-binding protein SRSF2-dependent alternative splicing signature in malignant proliferation of colorectal carcinoma. J Biol Chem. 2023; 299(2):102876. PMC: 9926302. DOI: 10.1016/j.jbc.2023.102876. View

Bergsma A, van der Wal E, Broeders M, van der Ploeg A, Pijnappel W . Alternative Splicing in Genetic Diseases: Improved Diagnosis and Novel Treatment Options. Int Rev Cell Mol Biol. 2018; 335:85-141. DOI: 10.1016/bs.ircmb.2017.07.008. View

10.

Perego S, Sansoni V, Banfi G, Lombardi G . Sodium butyrate has anti-proliferative, pro-differentiating, and immunomodulatory effects in osteosarcoma cells and counteracts the TNFα-induced low-grade inflammation. Int J Immunopathol Pharmacol. 2018; 32:394632017752240. PMC: 5849245. DOI: 10.1177/0394632017752240. View

11.

McGuire A, Pearson M, Neafsey D, Galagan J . Cross-kingdom patterns of alternative splicing and splice recognition. Genome Biol. 2008; 9(3):R50. PMC: 2397502. DOI: 10.1186/gb-2008-9-3-r50. View

12.

Pinci F, Gaidt M, Jung C, Nagl D, Kuut G, Hornung V . Tumor necrosis factor is a necroptosis-associated alarmin. Front Immunol. 2022; 13:1074440. PMC: 9791252. DOI: 10.3389/fimmu.2022.1074440. View

13.

Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A . Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003; 14(7):1126-34. DOI: 10.1093/annonc/mdg286. View

14.

Gonzalez-Blas C, De Winter S, Hulselmans G, Hecker N, Matetovici I, Christiaens V . SCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks. Nat Methods. 2023; 20(9):1355-1367. PMC: 10482700. DOI: 10.1038/s41592-023-01938-4. View

15.

Karni R, de Stanchina E, Lowe S, Sinha R, Mu D, Krainer A . The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14(3):185-93. PMC: 4595851. DOI: 10.1038/nsmb1209. View

16.

Whelan J, Seddon B, Perisoglou M . Management of osteosarcoma. Curr Treat Options Oncol. 2006; 7(6):444-55. DOI: 10.1007/s11864-006-0020-y. View

17.

Anczukow O, Rosenberg A, Akerman M, Das S, Zhan L, Karni R . The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012; 19(2):220-8. PMC: 3272117. DOI: 10.1038/nsmb.2207. View

18.

Yang J, Zhang C . Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020; 12(4):e1612. DOI: 10.1002/wnan.1612. View

19.

Pierrevelcin M, Flacher V, Mueller C, Vauchelles R, Guerin E, Lhermitte B . Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment. Adv Healthc Mater. 2022; 11(19):e2200195. DOI: 10.1002/adhm.202200195. View

20.

Long J, Caceres J . The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2008; 417(1):15-27. DOI: 10.1042/BJ20081501. View